Clinical Trials

StrateGIST Frontline: A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)

Link : https://www.clinicaltrials.gov/ct2/show/NCT07585266
Status : RECRUITING
Population : GIST 1st line
Description : IDRX-42 vs. imatinib
PI : A. Razak
Centers Opened : PMH
Phase : III
IIST/Pharma : Pharma